Overview

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate CancermCRPC

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Phase:
PHASE1
Details
Lead Sponsor:
TYK Medicines, Inc